Activated signaling in these models were consecutive to genetic modifications, such as expression of internal tandem duplications (ITD) or mutations in FLT3. On DNA extracted from post-HFD AML samples (n = 8 samples analyzed), we found no mutation or ITD in exons 14–15 of the Flt3 gene encoding the juxtamembrane domain, and no mutation were found in exon 20 encoding the tyrosine kinase domain (TKD) in the Flt3 gene (Supplementary Fig. S5). This evidence concerns the gene FLT3 and acute myeloid leukemia.